mA 相关基因特征的建立和验证可预测肝细胞癌的预后。

Development and validation of a mA-related gene signature for predicting the prognosis of hepatocellular carcinoma.

机构信息

Department of Emergency Surgery, Department of Emergency Medicine, The First affiliated hospital of Anhui Medical University, Heifei 230022, China.

Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.

出版信息

Biomark Med. 2020 Sep;14(13):1217-1228. doi: 10.2217/bmm-2020-0178.

DOI:10.2217/bmm-2020-0178

PMID:33021385

Abstract

This study aimed to investigate the prognostic role of mA methylation regulators in hepatocellular carcinoma (HCC). Gene expression matrices were downloaded from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium, and Gene Expression Omnibus databases. Univariate and multivariate regression analysis were utilized to determine the mA risk genes. Two mA-related risk genes (YTHDF1, YTHDF2) were identified in the TCGA HCC cohort. The mA-correlated risk score is an independent risk factor for the overall survival of the TCGA HCC cohort. Finally, we verified the reliability of our results using three external datasets. The mA-correlated gene signature has prognostic value in HCC patients and thus provides guidance for the treatment of HCC.

摘要

本研究旨在探讨 mA 甲基化调节剂在肝细胞癌（HCC）中的预后作用。从癌症基因组图谱（TCGA）、国际癌症基因组联盟和基因表达综合数据库下载基因表达矩阵。利用单变量和多变量回归分析确定 mA 风险基因。在 TCGA HCC 队列中确定了两个 mA 相关的风险基因（YTHDF1、YTHDF2）。mA 相关风险评分是 TCGA HCC 队列总生存期的独立危险因素。最后，我们使用三个外部数据集验证了我们结果的可靠性。mA 相关基因特征对 HCC 患者具有预后价值，因此为 HCC 的治疗提供了指导。